Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [pharmacology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

8 papers

TDX-2026-00025

Perioperative Dual Antiplatelet Therapy Management for Unprotected Left Main Coronary Artery Stenting Patients Requiring Elective Non-Cardiac Surgery: A Consensus-Based Approach

Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) require dual antiplatelet therapy (DAPT) to prevent stent thrombosis, a potentially catastrophic event. For unprotected left main coronary artery (ULMCA) PCI, guideline-recommended DAPT duration is typically 12 months. However, the need for elective non-cardiac surgery within this period presents a significant clinical dilemma, balancing the high risk of stent thrombosis if DAPT is prematurely discontinued against the increased bleeding risk during surgery if antiplatelets are continued. This paper synthesizes expert opinions from a clinical Q&A platform regarding the optimal management of a 71-year-old male who underwent ULMCA PCI with a Synergy everolimus-eluting stent 5 months prior and now requires an elective right hemicolectomy for well-differentiated adenocarcinoma. The consensus emphasizes delaying surgery to at least 9 months post-PCI if oncologically feasible. If surgery cannot be delayed, a bridging strategy with intravenous cangrelor is recommended, alongside aspirin continuation, meticulous perioperative monitoring, and a multidisciplinary team approach involving cardiology, oncology, surgery, and anesthesiology. This expert consensus highlights the critical need for individualized risk assessment, shared decision-making, and adherence to established protocols while acknowledging the limitations of current evidence specifically for ULMCA PCI in this high-risk scenario.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
3 contributors 118 votes 9 Apr 2026

TDX-2026-00023

Antifibrotic Therapy in Progressive Rheumatoid Arthritis-Associated Interstitial Lung Disease with a Usual Interstitial Pneumonia Pattern: Expert Perspectives on Treatment Selection and Monitoring

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) represents a significant cause of morbidity and mortality in patients with rheumatoid arthritis, particularly when presenting with a usual interstitial pneumonia (UIP) pattern and demonstrating progressive fibrosing characteristics. This paper synthesizes expert opinions from a clinical Q&A discussion regarding the management of a 58-year-old female with progressive RA-ILD (UIP pattern) despite immunosuppression. The primary clinical dilemma revolves around the selection between nintedanib and pirfenidone, the continuation of background immunosuppression, and optimal monitoring strategies. Expert consensus favored nintedanib as a first-line antifibrotic due to robust evidence from the INBUILD trial, particularly within the UIP subgroup. However, an alternative perspective highlighted pirfenidone's potential anti-inflammatory properties and institutional experience in connective tissue disease-associated ILD. Both experts strongly advocated for the continuation of mycophenolate, citing the potential for subclinical inflammation and the risks of disease flare or acceleration upon withdrawal. A comprehensive monitoring protocol incorporating FVC, 6-minute walk distance, patient-reported outcomes, and advanced techniques like home spirometry was recommended. This synthesis underscores the complexities of managing progressive RA-ILD, emphasizing evidence-based antifibrotic selection, judicious immunosuppression, and multi-modal monitoring to optimize patient outcomes.

2 contributors 58 votes 9 Apr 2026

TDX-2026-00022

Management of Probable Invasive Aspergillosis in Febrile Neutropenia in Resource-Variable Settings: A Synthesis of Expert Opinion and Pragmatic Strategies

Invasive aspergillosis (IA) represents a significant cause of morbidity and mortality in immunocompromised patients, particularly those with febrile neutropenia following intensive chemotherapy for acute myeloid leukemia. Current international guidelines advocate for voriconazole as first-line therapy for probable IA. However, the implementation of these recommendations is frequently challenged in resource-variable settings due to high drug costs, limited availability of advanced formulations, and lack of therapeutic drug monitoring (TDM) capabilities. This paper synthesizes expert clinical perspectives from a peer-vetted medical Q&A platform to address the practical dilemmas encountered in such environments. We explore the nuanced decision-making process concerning initial antifungal choice, the role of conventional amphotericin B deoxycholate with pragmatic modifications, and the criteria for escalating to combination therapy. The discussion highlights the critical need for context-specific strategies that balance evidence-based medicine with economic realities, aiming to optimize patient outcomes despite significant resource constraints. This synthesis provides valuable insights for clinicians navigating these complex scenarios.

2 contributors 75 votes 9 Apr 2026

TDX-2026-00017

Desensitization Strategies for Highly Sensitized Kidney Transplant Candidates with High-Titer Donor-Specific Antibodies: A Clinical Consensus and Evidence Review

Highly sensitized kidney transplant candidates, characterized by elevated calculated panel reactive antibody (cPRA) and high-titer donor-specific antibodies (DSA), face significant barriers to transplantation. This paper synthesizes expert clinical practice and current evidence regarding desensitization protocols for such challenging cases. Utilizing a community peer-reviewed clinical Q&A platform (tachyDx), expert opinions from two verified physicians, supported by 71 community votes, were analyzed to address critical questions concerning desensitization protocols for mean fluorescence intensity (MFI) >10,000, the role of imlifidase, and acceptable MFI thresholds for transplantation. **Background:** Highly sensitized kidney transplant candidates, often with a history of failed transplants, experience prolonged wait times and increased risk of antibody-mediated rejection (AMR). Effective desensitization protocols are crucial for expanding transplant access in this population. **Methods:** A clinical scenario involving a 34-year-old female with ESRD, cPRA 98%, and multiple high-titer DSAs (MFI up to 14,500) against a potential living donor was presented on the tachyDx platform. Two board-certified nephrology and transplant medicine specialists provided detailed responses, which were then peer-voted by 71 community physicians. This paper formally synthesizes these expert recommendations and integrates them with established medical literature. **Results:** A modified Johns Hopkins desensitization protocol, incorporating bortezomib, dexamethasone, plasmapheresis, IVIG, and rituximab, was proposed for MFI >10,000, demonstrating a 4/6 success rate in achieving transplantable MFI levels. Imlifidase (IdeS) was identified as a transformative rescue strategy, capable of rapidly cleaving IgG antibodies, with reported conversion rates to negative crossmatch exceeding 90% in clinical trials. Critical MFI thresholds for acceptable risk were defined as <5,000 for Class I and <3,000 for Class II DSA (particularly DQ), coupled with negative flow cytometry and C1q binding assays. DQ antibodies were highlighted as a significant concern due to their strong association with AMR. **Conclusions:** Effective management of highly sensitized kidney transplant candidates requires multi-agent desensitization strategies, judicious use of novel agents like imlifidase, and stringent MFI thresholds. Individualized protocols and close post-transplant monitoring are essential to mitigate the risk of AMR and improve graft outcomes in this complex patient population.

2 contributors 71 votes 9 Apr 2026

TDX-2026-00012

Optimizing Malignant Hyperthermia Management: A Peer-Reviewed Consensus on Dantrolene Reconstitution and Crisis Protocols

Background: Malignant Hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine. Rapid diagnosis and immediate administration of dantrolene are critical for patient survival. However, the traditional reconstitution process for dantrolene sodium can be time-consuming, potentially delaying definitive treatment during an acute crisis. This paper synthesizes expert opinions on practical solutions to mitigate these delays and optimize overall MH management. Methods: This study utilized a community peer-reviewed clinical Q&A discussion platform, tachyDx, involving two verified physician contributors and garnering 55 peer votes. The discussion focused on practical challenges related to dantrolene reconstitution during suspected MH and parallel management strategies. Expert responses were analyzed to identify consensus and divergent practices regarding dantrolene stocking, availability of concentrated formulations, concurrent therapeutic interventions, and post-crisis monitoring. Results: Key findings include a consensus on increased dantrolene stocking (e.g., 36 vials of classic dantrolene) and the significant advantage of concentrated formulations like Ryanodex for rapid administration. Parallel management strategies emphasized immediate anesthetic cessation, hyperventilation, aggressive active cooling, and prompt treatment of hyperkalemia. Post-crisis care protocols highlighted the necessity for continuous monitoring in an intensive care unit for at least 24 hours, serial laboratory assessments, maintenance dantrolene dosing, and crucial genetic counseling for affected families. Conclusions: Efficient dantrolene administration, supported by adequate stocking, rapid-reconstitution formulations, and well-drilled parallel management protocols, is paramount in MH crisis. Comprehensive post-crisis care, including genetic counseling, is essential for patient safety and family screening. These insights underscore the need for robust institutional protocols and continuous education to improve outcomes in MH.

2 contributors 55 votes 6 Apr 2026

TDX-2026-00007

Optimizing Bedaquiline-Based Regimens for Pre-Extensively Drug-Resistant Tuberculosis in HIV Co-infection: A Community Peer-Reviewed Clinical Consensus

Background: Pre-extensively drug-resistant tuberculosis (pre-XDR TB), characterized by resistance to isoniazid, rifampicin, and fluoroquinolones, presents a significant global health challenge, particularly in individuals co-infected with human immunodeficiency virus (HIV). The advent of novel anti-TB agents and shorter regimens, such as bedaquiline-pretomanid-linezolid (BPaL), offers improved outcomes but necessitates careful consideration of regimen composition, drug dosing, adverse event monitoring, and drug-drug interactions. Methods: This study synthesizes expert clinical opinion derived from a peer-reviewed clinical Q&A platform (tachyDx), involving two verified physicians and garnering 54 community peer votes. A clinical scenario involving a 34-year-old female with pre-XDR TB and HIV co-infection was presented, prompting discussion on regimen selection, linezolid management, QTc monitoring, antiretroviral therapy (ART) timing, and drug interactions. The accepted answer and additional insights were critically analyzed to establish a consensus. Results: The BPaL regimen was strongly favored for its shorter duration and high efficacy, contingent on pretomanid availability. Optimal linezolid dosing was identified as 600 mg daily for 26 weeks, with rigorous hematologic and neurologic monitoring. A comprehensive QTc monitoring protocol for bedaquiline, particularly in the context of dolutegravir (DTG) co-administration, was outlined. Continuation of existing ART was recommended, with specific guidance for ART-naïve patients. Critical drug-drug interactions, including those involving CYP3A4 inhibitors/inducers and monoamine oxidase inhibitors, were highlighted. Conclusions: This expert consensus provides practical, evidence-informed guidance for managing pre-XDR TB in HIV co-infected patients, emphasizing the BPaL regimen, meticulous adverse event monitoring, and proactive management of drug interactions. These recommendations aim to facilitate the safe and effective implementation of novel TB therapies in complex clinical settings.

2 contributors 54 votes 6 Apr 2026

TDX-2026-00003

Evidence-Based Framework for Refractory Status Epilepticus Management: A Community Peer-Reviewed Clinical Consensus

Background: Refractory status epilepticus (RSE) represents a neurological emergency associated with significant morbidity and mortality, characterized by persistent seizure activity despite the administration of adequate doses of at least two antiepileptic drugs, including a benzodiazepine. Optimal management strategies for RSE, particularly regarding continuous infusion agents, electroencephalographic targets, and the timing of etiologic investigations, remain subjects of ongoing clinical debate and require expert consensus. Methods: This paper synthesizes expert opinions derived from a structured, community peer-reviewed clinical discussion on the tachyDx platform. Three verified physicians, specializing in neurology and critical care, contributed to a case-based scenario of a 32-year-old female presenting with new-onset RSE. Their responses underwent peer evaluation by 106 community physicians. Results: Consensus emerged on several critical aspects of RSE management. Midazolam infusion was favored over propofol as a first-line continuous agent due to concerns regarding Propofol Infusion Syndrome (PRIS). The initial electroencephalographic target was seizure suppression, with escalation to burst-suppression reserved for persistent seizures. Infusions were typically maintained for 24-48 hours post-seizure cessation. Ketamine was identified as a valuable second-line continuous infusion. Early immunologic workup, particularly for anti-NMDA receptor encephalitis, was strongly recommended in new-onset RSE without clear etiology. Meticulous hemodynamic and electrolyte management was emphasized. Conclusions: The synthesized expert consensus provides a practical, evidence-informed framework for managing RSE, highlighting the importance of a multidisciplinary approach, careful agent selection, individualized electroencephalographic targets, and prompt etiologic investigation, especially for autoimmune causes.

3 contributors 106 votes 6 Apr 2026

TDX-2026-00001

Evidence-Based Framework for Vasopressor and Inotrope Sequencing in Septic Shock with Concurrent Right Ventricular Failure: A Community Peer-Reviewed Clinical Consensus

Background: Septic shock frequently leads to complex hemodynamic instability, often complicated by acute right ventricular (RV) failure. This co-occurrence significantly increases morbidity and mortality, presenting a therapeutic challenge due to the intricate interplay between systemic vasodilation, elevated pulmonary vascular resistance (PVR), and myocardial dysfunction. Optimal vasopressor and inotropic agent sequencing in this specific clinical scenario remains a subject of ongoing debate and lacks definitive guideline recommendations. Methods: This consensus paper synthesizes expert opinions from a clinical Q&A discussion hosted on a specialized physician peer-review platform. Five verified critical care and cardiology specialists contributed to the discussion, which garnered 130 community peer votes. The methodology involved a structured analysis of proposed treatment algorithms, evaluation of supporting evidence, and identification of key monitoring parameters to establish a practical, stepwise approach. Results: A consensus emerged advocating for early initiation of vasopressin (0.03-0.04 U/min) as an adjunct to norepinephrine, prioritizing its favorable PVR profile over further norepinephrine escalation. Low-dose dobutamine (2.5-5 mcg/kg/min) was recommended for targeted RV inotropic support once mean arterial pressure was stabilized. In cases of refractory RV dysfunction, inhaled epoprostenol (20-50 ng/kg/min) was endorsed for selective pulmonary vasodilation. Agents such as phenylephrine and milrinone were strongly discouraged due to their potential to exacerbate RV afterload or systemic hypotension, respectively. Conclusions: This consensus provides a structured, evidence-informed approach to vasopressor and inotrope sequencing in septic shock with concurrent RV failure. The recommendations emphasize a physiologically guided strategy, prioritizing agents that minimize RV afterload while supporting contractility, alongside vigilant hemodynamic and echocardiographic monitoring. This framework aims to guide clinicians in managing this high-risk patient population.

5 contributors 130 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1